<DOC>
	<DOC>NCT02550418</DOC>
	<brief_summary>The purpose of the trial is to evaluate the efficacy of an 8 week treatment with once-daily 9 mg budesonide in patients with active ulcerative colitis</brief_summary>
	<brief_title>Budesonide 9 mg Capsules in Active UC</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Signed informed consent, Men or women aged 18 to 75 years, Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by endoscopy and histology, Established disease, Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis, incomplete microscopic colitis), diverticular disease associated colitis, Toxic megacolon or fulminant colitis, Colon resection, Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile toxin in stool culture at screening), Malabsorption syndromes, Celiac disease, Bleeding hemorrhoids, Active peptic ulcer disease Other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding, Hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured, Any severe infectious disease (e.g., tuberculosis, AIDS), Severe comorbidity substantially reducing life expectancy, History of colorectal cancer, History of cancer (other than colorectal) in the last 5 years, except for basal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>